Drug intelligence / Profile preview

AX-012

Development stage: Preclinical
Lead developer: Axiom Biosciences
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

AX-012 is a preclinical-stage recombinant fusion protein being developed by Axiom Biosciences for the treatment of atopic dermatitis. The drug was engineered using the company's proprietary AI-driven computational design platform, which aims to optimize the structural and functional properties of protein therapeutics. While the specific molecular target of AX-012 has not been publicly disclosed, the program is part of Axiom's pipeline of AI-designed biologics targeting chronic inflammatory conditions. As of 2024, the asset remains in the discovery and preclinical validation phase.

Beyond the preview

Go deeper on AX-012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AX-012.

Explore the full profile